Bangkok Lab and Cosmetic PCL
SET:BLC
Bangkok Lab and Cosmetic PCL
Other
Bangkok Lab and Cosmetic PCL
Other Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
B
|
Bangkok Lab and Cosmetic PCL
SET:BLC
|
Other
-฿16.3m
|
CAGR 3-Years
28%
|
CAGR 5-Years
18%
|
CAGR 10-Years
N/A
|
|
|
M
|
Mega Lifesciences PCL
SET:MEGA
|
Other
-฿47m
|
CAGR 3-Years
-9%
|
CAGR 5-Years
7%
|
CAGR 10-Years
-14%
|
|
Bangkok Lab and Cosmetic PCL
Glance View
Bangkok Lab & Cosmetic PCL engaes in the provision of pharmaceuticals and health products. The company is headquartered in Bangkok, Bangkok Metropolis. The company went IPO on 2023-06-21. The firm is engaged in the production of medicines and health products by selecting raw materials. The firm has produced more than 100 products. Its products include ZENZERA 200 SUSPENSION, ZENZERA, SYNOVAR UC40, RADIARA, PROCEMINE, FANGO-B, EMBLICOF COUGH MIXTURE, CLINIGEL STERILE, RAQUA FIBROTA, RAQUA COLLAGEN, SYNOVAR UC, SYNOVAR POWDER, NACOXIB, LUTI-BERRY MIXED, ZIGA GEL (orange), ZERTINE SYRUP, VIZO Cream, SPORAXYL CREAM, NORAPHEN, MURHINOL-250 SYRUP, NORFLOXYL 400, NOCID, MURHINOL-250 SYRUP, MUCOBROX, GYNOSTEN CREAM, and GYNOSTEN 500, AROTIKA COOL GEL, ALLERAX-FC, AROTIKA RUB LOTION (SPRAY), Calza c Dietary Supplement, Calza PLUS POWDER Dietary, and Calza-750 TAB FC, among others. Its products are distributed through Bangkok Drug Co., Ltd., Beereach (Thailand) Co., Ltd., Pharmaline Company Limited, Pharma Alliance Company Ltd., and Bangkok Medica Co., Ltd.
See Also
What is Bangkok Lab and Cosmetic PCL's Other?
Other
-16.3m
THB
Based on the financial report for Dec 31, 2024, Bangkok Lab and Cosmetic PCL's Other amounts to -16.3m THB.
What is Bangkok Lab and Cosmetic PCL's Other growth rate?
Other CAGR 5Y
18%
Over the last year, the Other growth was 79%. The average annual Other growth rates for Bangkok Lab and Cosmetic PCL have been 28% over the past three years , 18% over the past five years .
